NCT06329882 Doxycycline in Type II Diabetes
| NCT ID | NCT06329882 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Mostafa Bahaa |
| Condition | Diabetes Mellitus, Type 2 |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-03-30 |
| Primary Completion | 2026-03-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2024-03-30 with a primary completion date of 2026-03-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Eligibility Criteria
Inclusion Criteria: * Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5 Exclusion Criteria: * Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation
Frequently Asked Questions
Who can join the NCT06329882 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 60 Years, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06329882 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06329882 currently recruiting?
Yes, NCT06329882 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mostafa Bahaa to inquire about joining.
Where is the NCT06329882 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT06329882 clinical trial?
NCT06329882 is sponsored by Mostafa Bahaa. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.